Placebo effect in technical applications increases risk-taking behavior

Human augmentation technologies refer to technological aids that enhance human abilities. They include things like exoskeletons, but also augmented reality headsets. A study at the Chair of Human-Centered Ubiquitous Media at LMU has now shown that users have high expectations of the effects of these technologies. As soon as they believe that AI is enhancing their cognitive abilities, they increase their risk-taking. And they do this independently of whether the AI is actually assisting them.

The hype around AI applications affects the expectations of users. This can lead to riskier behavior."

Steeven Villa, doctoral researcher at the Chair of Human-Centered Ubiquitous Media and lead author of the study

Ruling out placebo effects

In the study, participants were informed they would be assisted by an AI application that augments their cognitive abilities during a virtual card game. In reality, there was no such AI enhancement. Nevertheless, the participants exhibited higher risk-taking as soon as they believed they were benefiting from AI.

The study points to the possible existence of a placebo effect in technical applications of this nature, akin to the well-established placebo effect for medication. "At a time when people are increasingly interacting with intelligent systems, it's important to understand a possible placebo effect so that we can build systems that offer genuine support," says Albrecht Schmidt, Professor of Computer Science at LMU. The researchers recommend assessing the actual benefit of AI applications before releasing them, taking possible placebo effects into account. In addition, they advise tech companies to involve users and their expectations to a greater extent in the development process.

Journal reference:

Villa, S., et al. (2023) The placebo effect of human augmentation: Anticipating cognitive augmentation increases risk-taking behavior. Computers in Human Behavior.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease